Search

everythinglearnresearchcommunity

for

Search:↓

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.

308-nm excimer light therapy helped over a third of treatment-resistant alopecia universalis patients regrow most of their hair.

Asian patients with Frontal Fibrosing Alopecia often lose eyebrow hair and respond well to combined antiandrogen or antimalarial and topical treatments.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Use the least toxic, most specific treatments for skin diseases, considering side effects and individual patient needs.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Upadacitinib improved multiple immune-related conditions in one patient.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Brodalumab is more effective than ustekinumab for treating psoriasis.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

UDCA reduces inflammation and joint damage in rheumatoid arthritis.

Infliximab may cause hair loss in Crohn's disease patients.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Membership in a self-help organization is linked to being better informed and having a higher education, but it doesn't clearly affect disease outcomes.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.

Leflunomide is effective for rheumatoid arthritis but has significant side effects.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.